Previous 10 | Next 10 |
2024-02-28 07:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 44 th Annual Healthcare Conference, on Wednesday March 6 th at 1:30 pm ET. Barclays 26 th Annual Global Healthcare Confere...
2024-02-28 06:38:00 ET Regarding Moderna (NASDAQ: MRNA) stock, RBC Capital analyst Luca Issi is bullish. Per his price target of $125 that he reiterated on Feb. 23, the biotech's shares could rise by 30% to reach $125. There are a few upcoming developments that could stimulate the s...
2024-02-26 09:15:03 ET HSBC analyst issues REDUCE recommendation for MRNA on February 26, 2024 08:11AM ET. The previous analyst recommendation was Hold. MRNA was trading at $93.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-02-23 16:52:40 ET Summary Moderna, Inc.'s market share for the Spikevax vaccine is increasing, but the company faces a tough 2024 with expected revenue slumps. The new respiratory vaccine has questioned efficacy and is late to market, potentially impacting the sales potential...
2024-02-23 11:09:43 ET Summary Novavax, Inc. soars after settling Covid-19 vaccine dispute and positive peer numbers, but the future remains bleak with the cash balance under pressure. The settlement with Gavi requires Novavax to pay $475 million through 2028, potentially totaling...
2024-02-22 12:30:13 ET Image source: The Motley Fool. Moderna (NASDAQ: MRNA) Q4 2023 Earnings Call Feb 22, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Moderna (MRNA) Q4 2023 Earnings Call Transcript
2024-02-22 11:55:14 ET Summary Generation Bio has lost around 70% of its value in the past two years because of the high risks associated with its non-viral gene therapy. The company has pivoted to focus on targeted lipid nanoparticles and immune silent DNA, but these directions m...
2024-02-21 13:58:16 ET More on Moderna Buy Moderna's Turnaround Thesis While Market Pessimism Lasts Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World Moderna: Fade 2025 Outlook Earnings week ahead: NVIDIA, Walmart, Home Depot, Lucid a...
2024-02-20 09:00:00 ET Summary Moderna has surged 40% from its November 2023 lows through last week's close. Buyers returned to buy the "bad news" from its Q3 earnings reset. The recent worse-than-anticipated data release for its RSV vaccine contributed to a recent pullback in MRN...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...